Human Genome Sciences to Host November 2nd Conference Call to Discuss Top-Line Results from Second Phase 3 Trial of BENLYSTA(TM) (Belimumab) in Systemic Lupus Erythematosus

ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq:HGSI) today announced that it expects to have top-line 52-week results available on Monday, November 2nd, from BLISS-76, the second of two pivotal Phase 3 clinical trials of BENLYSTA™ (belimumab) in systemic lupus erythematosus (SLE).